Abstract
The present study reports the duration of immunity and protective efficacy of Peste des Petits Ruminants (PPR) vaccine (Nigerian strain 75/1) in sheep and goats. A total of 105 sheep and goats were divided into three groups A, B and C. Group A received normal recommended dose (1.0 ml) of PPR vaccine, group B received half dose (0.5 ml) of PPR vaccine and group C was kept as unvaccinated control group in contact with vaccinated animals. The post vaccination dynamics of antibodies against PPR virus was studied. It was found that significant antibody titres persisted for 3 years post vaccination in sheep and goats vaccinated with either full dose or half dose of PPR vaccine. The challenge protection studies were carried out in experimental animals at 24 and 36 month post vaccination. The vaccinates withstood challenge and were found completely resistant clinically and virologically to virulent PPR virus for 24 and 36 months post vaccination. The unvaccinated control animals developed typical clinical signs of PPR and the challenged virus was detected in ocular, nasal and oral secretions of these animals. This study demonstrated that a single immunization with PPR vaccine conferred solid protection in sheep and goats for 3 years.
Highlights
Peste des petits ruminant (PPR) is an acknowledged acute and highly contagious newly emerging/evolving disease of small ruminants
The highest mean PI value of more than 90% was observed on day 30 post vaccination in the animals in group A which received normal recommended dose of PPR vaccine
A similar trend was observed in the animal vaccinated with half dose of PPR vaccine
Summary
Peste des petits ruminant (PPR) is an acknowledged acute and highly contagious newly emerging/evolving disease of small ruminants. The disease is caused by a Morbilli virus of genus paramyxoviridae [1]. The disease has been a cause of heavy mortality among small ruminants in Pakistan since last decade [4]. Tissue culture rinderpest vaccine (TCRV) was used for control of PPR in Pakistan. A homologous PPR vaccine (Nigerian strain 75/1) appears to be the only remedy in this regard. Very limited information is available about the duration of immunity and protective efficacy of this vaccine. A study was designed to evaluate the duration of immunity and protective efficacy of the homologous PPR vaccine.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
